Zentalis Pharmaceuticals (NASDAQ:ZNTL) PT Lowered to $20.00 at HC Wainwright

Zentalis Pharmaceuticals (NASDAQ:ZNTLFree Report) had its price target reduced by HC Wainwright from $40.00 to $20.00 in a research note published on Tuesday, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other equities analysts have also issued reports on ZNTL. Wedbush lowered shares of Zentalis Pharmaceuticals from a neutral rating to an underperform rating and cut their price target for the stock from $15.00 to $4.00 in a report on Tuesday. Wells Fargo & Company downgraded shares of Zentalis Pharmaceuticals from an overweight rating to an equal weight rating and decreased their target price for the company from $29.00 to $9.00 in a research report on Tuesday. Finally, Stifel Nicolaus decreased their target price on shares of Zentalis Pharmaceuticals from $32.00 to $10.00 and set a buy rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of Hold and an average price target of $11.33.

Read Our Latest Analysis on Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Stock Up 26.8 %

Shares of ZNTL stock opened at $5.25 on Tuesday. The firm has a market cap of $372.91 million, a price-to-earnings ratio of -1.59 and a beta of 1.83. The company’s 50 day moving average is $11.32 and its 200 day moving average is $13.02. Zentalis Pharmaceuticals has a 52-week low of $3.93 and a 52-week high of $30.53.

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.91. The business had revenue of $40.56 million for the quarter, compared to analysts’ expectations of $35.00 million. During the same period in the previous year, the business earned ($1.07) earnings per share. Analysts anticipate that Zentalis Pharmaceuticals will post -2.72 EPS for the current fiscal year.

Insider Activity at Zentalis Pharmaceuticals

In related news, insider Diana Hausman sold 3,356 shares of the company’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $12.62, for a total transaction of $42,352.72. Following the completion of the sale, the insider now owns 373,876 shares of the company’s stock, valued at approximately $4,718,315.12. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, insider Diana Hausman sold 3,356 shares of the company’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $12.62, for a total transaction of $42,352.72. Following the completion of the sale, the insider now owns 373,876 shares of the company’s stock, valued at approximately $4,718,315.12. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Cam Gallagher sold 9,597 shares of the company’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $11.98, for a total transaction of $114,972.06. Following the sale, the chief financial officer now directly owns 633,680 shares of the company’s stock, valued at approximately $7,591,486.40. The disclosure for this sale can be found here. 6.10% of the stock is owned by corporate insiders.

Institutional Trading of Zentalis Pharmaceuticals

Several hedge funds have recently made changes to their positions in ZNTL. Charles Schwab Investment Management Inc. grew its stake in shares of Zentalis Pharmaceuticals by 8.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,064 shares of the company’s stock valued at $8,868,000 after buying an additional 36,219 shares during the period. Healthcare of Ontario Pension Plan Trust Fund grew its stake in shares of Zentalis Pharmaceuticals by 176.5% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 47,000 shares of the company’s stock valued at $943,000 after buying an additional 30,000 shares during the period. Qube Research & Technologies Ltd purchased a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at approximately $2,836,000. Eventide Asset Management LLC grew its stake in shares of Zentalis Pharmaceuticals by 13.6% in the 3rd quarter. Eventide Asset Management LLC now owns 7,814,039 shares of the company’s stock valued at $156,750,000 after buying an additional 936,236 shares during the period. Finally, Alps Advisors Inc. grew its stake in shares of Zentalis Pharmaceuticals by 19.2% in the 3rd quarter. Alps Advisors Inc. now owns 52,125 shares of the company’s stock valued at $1,046,000 after buying an additional 8,407 shares during the period.

About Zentalis Pharmaceuticals

(Get Free Report)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

Featured Stories

Analyst Recommendations for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.